Form 4: PTC Therapeutics Executive Sells Shares Under 10b5-1 Plan
Statement of Changes in Beneficial Ownership
Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics, reported the sale of common stock under a pre-arranged trading plan.
Summary
- Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics, Inc., executed a series of transactions involving the sale of common stock.
- These sales occurred on April 1, 2026, and were conducted under a Rule 10b5-1 trading plan adopted on November 11, 2025.
- A total of 39,393 shares were sold at a weighted average price of $68.89, with individual transactions ranging from $68.26 to $69.26.
- An additional 12,530 shares were sold at a weighted average price of $69.50, with prices ranging from $69.26 to $70.13.
- A smaller transaction involved 80 shares sold at $70.30.
- Following these transactions, Almstead beneficially owns 72,747 shares directly and 2,737 shares indirectly through his spouse.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as the transactions were conducted under a pre-arranged 10b5-1 plan, indicating a planned divestment rather than a reaction to material non-public information.
Negatives
- Insider selling can sometimes be perceived negatively by the market, although this transaction was conducted under a pre-established 10b5-1 plan.
Future Outlook
No specific future outlook or guidance is provided in this filing, as it pertains to insider stock transactions.
Industry Context
StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common and are designed to provide an affirmative defense against allegations of insider trading by allowing executives to sell shares at predetermined times and prices. This filing indicates routine portfolio management by an executive.
Stakeholder Impact
- Shareholders may note the sale of shares by a key executive, though the 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 11/11/2025 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 04/01/2026 | Date of the reported stock transactions. |
| 04/03/2026 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Keywords
PTC Therapeutics, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Neil Gregory Almstead, PTCT
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.